secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001193125-24-072706
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal raises ~$574M in public offering for Rezdiffra launch
--------------------------------------------------------------

- Offering of 750,000 shares at $260/share and 1,557,692 pre-funded warrants at $259.9999 each.
- Net proceeds estimated at ~$574M; underwriters have 30-day option for up to 346,153 additional shares.
- Proceeds to fund commercial launch of Rezdiffra (resmetirom) in the U.S. and for general corporate purposes.
- Closing expected March 21, 2024; lock-up agreements for directors and officers for 60 days.
- Underwriters include Goldman Sachs, Jefferies, Cowen, Evercore, Piper Sandler.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524072706/0001193125-24-072706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524072706/d774533d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-072706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer